



Cytokind is a team of experienced MedTech entrepreneurs, scientists, and value-based modelers committed to improving the lives and longevity of patients with auto-immune diseases. The prevalence of auto-immune disorders in the US is >15x that of cancer. It is also underappreciated as a women’s health issue affecting 2.5 – 3x more women than men. Cytokind’s first indication in auto-immunity will be for Multiple Sclerosis (MS) with a translational application of a safe and effective treatment for patients @home – all within a value-based care revenue model. The team has >60 years of medical device start-up expertise with multiple acquisitions and IPOs. Our SAB includes a scientist nominated for the Nobel Prize.

Market: Systemic inflammation is upstream of many chronic auto-immune disorders and is one of the hallmarks of aging. MS is one such disease. It is a non-curable chronic condition, driven by immune dysregulation and neuroinflammation, affecting ~1M people in the US with an annual burden on US health care of >\$85B. Neurologists know MS as the most-light sensitive disease in the world, where the lack of sunlight’s UV-B rays leads to worse MS outcomes. This provides Cytokind a treatment window to exploit.

Answering the Call to Action: The extensive research on UV-B light and MS culminated in a 2022 call to action in the American Academy of Neurologists’ journal [Neurology](#) for a trial of phototherapy using UV-B lights for MS patients with parallel OMICs assessments. Cytokind is the right team at the right time, with global leadership in phototherapy, including the PI of the largest UV-B light trial for MS. Prof. Hart’s Phase 1 results predict phototherapy will reduce inflammation, stabilize immunity, and drive down utilization costs. We expect to confirm these clinical and economic benefits in a phase 2 trial.

MS is the most-light sensitive disease in the world, providing Cytokind a new therapeutic treatment window.

Clinical Need: A translational application of @home UV-B phototherapy in a value-based care model combined with a digital companion app to support compliance and engagement is a win for patients, payers, and providers.

Our Solution: We provide MS patients with FDA-cleared, web-enabled, UV-B lights @home. Cytokind’s manufacturing partner is [Daavlin](#) - the world’s leader in phototherapy. Our phase 2 trial will provide a proprietary new indication for MS.



The Economic Opportunity: Our value-based modeling predicts monthly savings of >\$240/month per participant. Based on 1M US patients, this is a \$4.8B TAM. Economic benefits include reducing hospital visits and utilization costs. Comparable @home intervention and behavioral coaching exits include [Cricket Health, part of a \\$2.4B merger with Fresenius](#), and [Propeller Health, acquired by Resmed for \\$225M](#). Other light-sensitive auto-immune diseases driven by inflammation include ALS, Alzheimer’s, and hypertension. Cytokind has a **Grand Slam upside** from each clinical trial. We are treating UV-B as if it were a new cancer drug, and we **include proprietary OMICs** to uncover the underlying UV-B induced compounds as a novel therapeutic to stabilize systemic inflammation for all of auto-immunity and longevity.

The Team: The team includes seasoned MedTech CEOs with multiple IPOs and exits in excess of \$2B. Our SAB includes a scientist twice nominated for the Nobel Prize – Hector DeLuca, PhD.

Board of Directors

[Greg Casciaro](#)
[John MacMahon](#)
[Ben Wang, PhD](#)

Strategic Advisors

[John Milligan](#)
[Evan Anderson](#)
[Nichole Abla](#)

Scientific Advisors

[Ahmed Obeidat, MD, PhD](#)
[Hector DeLuca, PhD](#)
[Prue Hart, PhD](#)
[Carmen Castilla, MD](#)
[Richard Weller, MD](#)

Series A Funding and use of Proceeds: We are raising \$15M for our Phase 2 trial to validate the clinical and economic impact and achieve 1st revenue within 18 months.